Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isosorbide dinitrate for prevention of spinal bone loss in chronic kidney disease
ACTRN12614000049673Phase 3Not yet recruiting
- Sponsor
- University of Melbourne
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in chronic kidney disease (CKD), osteopenia and osteoporosis comparing Isosorbide dinitrate with Placebo (2 arms). Primary endpoints: Spinal bone mineral density and Serum alkaline phosphatase. Planned start Apr 2014; status: not yet recruiting.
02
Drugs
isosorbide dinitrate
03
Conditions
chronic kidney disease (CKD)osteopeniaosteoporosis
Beyond the preview
Go deeper on ACTRN12614000049673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000049673.